v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
Column | Value |
---|---|
Trial registration number | NCT04343976 |
Full text link
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
|
First author
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
|
Contact
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
JLGustafson@mgh.harvard.edu |
Registration date
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
2020-04-14 |
Recruitment status
Last imported at : Oct. 12, 2021, 1 p.m. Source : ClinicalTrials.gov |
Terminated |
Study design
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
RCT |
Allocation
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Randomized |
Design
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Parallel |
Masking
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Blind label |
Center
Last imported at : March 15, 2023, 4 a.m. Source : ClinicalTrials.gov |
single-center |
Study aim
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Treatment |
Inclusion criteria
Last imported at : Dec. 13, 2020, 12:31 a.m. Source : ClinicalTrials.gov |
inclusion criteria: - able to provide informed consent - confirmed covid-19 diagnosis based on pcr analysis of respiratory secretions - positive sars-cov-2 rt-pcr test must be within 48 hours of randomization |
Exclusion criteria
Last imported at : April 11, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
- clinically-significant illness or any other major medical disorder that in the opinion of the investigator, may interfere with subject treatment, assessment or compliance with the protocol - treatment with ifn or other immunomodulatory/immunosuppressive agent within 12 months before screening. - respiratory compromise requiring ventilatory support other than nasal cannula (mask, bipap or intubation and mechanical ventilation) - history of treatment with any of the following medications within five half-lives or 30 days before administration of the study drug (whichever is longer): anti-il-6, anti-il6r antagonists, janus kinase inhibitors, ustekinumab (anti-il-12/23), or anti il-23 agents (guselkumab). - life threatening sae during the screening period - pregnant or nursing females - platelet count <90,000 cells/mm3 - wbc count <3,000 cells/mm3 - anc <1,500 cells/mm3 - hb <11 g/dl for women and <12 g/dl for men - crcl < 50 ml/min - bilirubin level ≥ 1.5x uln - inr ≥1.5 (except in the setting of concomitant anticoagulant use) - crp > 200 mg/l - clinically-relevant alcohol or drug abuse within 12 months of screening - known hypersensitivity to interferons - current or planned participation in an investigational new drug (ind) trial from 30-days prior to randomization through day 14 post treatment |
Number of arms
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
2 |
Funding
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Raymond Chung |
Inclusion age min
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
18 |
Inclusion age max
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
None |
Countries
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
United States |
Type of patients
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Mild/moderate disease at enrollment |
Severity scale
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
2: Mild/moderate disease at enrollment |
Total sample size
Last imported at : July 31, 2021, 1 p.m. Source : ClinicalTrials.gov |
14 |
primary outcome
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Undetectable COVID PCR at day 7 |
Notes
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
None |
Phase
Last imported at : Feb. 25, 2021, 7:58 p.m. Source : ClinicalTrials.gov |
Phase 2 |
Arms
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
[{"arm_notes": "", "treatment_id": 674, "treatment_name": "Interferon lambda", "treatment_type": "Interferons", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}] |